Pharma in the crosshairs: How the FTC is expanding its antitrust powers under its new chair

Less than a month since her Senate confirmation, the new, young and staunchly progressive Federal Trade Commission chair Lina Khan is ready to up the pressure on unfair business practices, including at the largest pharma companies. To do that, Khan is rolling back restrictions on antitrust investigations and potentially opening the flood gates on Big Pharma M&A.